Rheumatoid Arthritis Clinical Trial
— EROMOfficial title:
Nutritional Intervention in Rheumatic Diseases: Effect of Marine Omega-3 Fatty Acids and Individual Dietary Guidance
NCT number | NCT04586933 |
Other study ID # | 79907 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | December 10, 2020 |
Est. completion date | June 10, 2025 |
Background: Patients with inflammatory rheumatic diseases (IRD) are prone to malnutrition for several reasons. The diseases and treatment can cause reduced intake and absorption of nutrients and the inflammatory processes may cause an increased demand for nutrients, especially proteins. Studies report that nutritional status can affect disease activity. Dietary supplement of 3-4 gram omega-3 has shown beneficial effect upon disease activity in patients with IRD. Aim: To investigate whether improved dietary intake with and without supplements of omega-3 will affect disease activity in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). Hypothesis 1: A systematic change of diet in line with the Norwegian dietary guidelines, which will result in increased intake of, among other nutrients, omega-3 fatty acids and complete protein, as well as reduced intake of saturated fat and sugar, will improve nutritional status and reduce disease activity. Hypothesis 2: A systematic change of diet (as above), included a high dose of omega-3 will further improve nutritional status and reduce disease activity compared with placebo. Design: A DB-RCT-study will be conducted. All patients will receive individualized dietary guidance by a clinical dietician for 12 weeks, before randomization to supplements of omega-3 or placebo, for 24 weeks. The supplement will be blinded for the participants, researchers and physicians. Clinical implications: The study will investigate the effect of improved diet and nutrition on treatment offered to patients with IRD to provide more evidence-based knowledge, and thus specific dietary guidelines for patients with IRD. In addition, the study might increase the understanding of the role of omega-3 in the pathogenesis of inflammation.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | June 10, 2025 |
Est. primary completion date | June 10, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients must be diagnosed with one of the following diagnoses: rheumatoid arthritis, according to the ACR / EULAR 2010 criteria, psoriatic arthritis, according to the CASPAR criteria, axial spondylarthritis, including ankylosing spondylarthritis and non-radiographic spondylarthritis, according to the ASAS criteria - Duration of illness =0.5 years - Between 18 and 75 years - Understand Norwegian - The patient has given informed consent to participate - No change in medication the last 12 weeks before inclusion Exclusion Criteria: Diagnoses / conditions that make it difficult to follow a dietary intervention and / or supplementation of omega-3s, including: - Conditions or use of medications where omega-3 is contraindicated - Pregnancy / lactation - Allergy to soy or fish - Severe liver disease - Severe mental or physical illnesses, such as insulin-requiring diabetes |
Country | Name | City | State |
---|---|---|---|
Norway | Haukeland University Hospital | Bergen | Vestland |
Lead Sponsor | Collaborator |
---|---|
Haukeland University Hospital | GC Rieber Oils AS |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | DAS28 (Disease Activity Score 28-joint count) | Disease activity score, higher values indicate a higher disease activity and below 2.6 meaning remission. | Change between week 0, 12, 24, 36 and 52 | |
Primary | ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score) | Disease activity score, higher values indicate a higher disease activity | Change between week 0, 12, 24, 36 and 52 | |
Primary | DAPSA (Disease Activity Index for Psoriatic Arthritis) | Disease activity score, higher values indicate a higher disease activity and below 4 meaning remission | Change between week 0, 12, 24, 36 and 52 | |
Secondary | RAID (Rheumatoid Arthritis Impact of Disease) | Disease activity scores and scores evaluating quality of life, range 0-10, and higher scores indicate a higher grade of disability | Change between week 0, 12, 24, 36 and 52 | |
Secondary | RAND12 (short form health survey) | Disease activity scores and scores evaluating quality of life | Change between week 0, 12, 24, 36 and 52 | |
Secondary | MHAQ (Modified Health Assessment Questionnaire) | Disease activity scores and scores evaluating quality of life, range from 0 to 3 while higher values indicate a higher grade of disability | Change between week 0, 12, 24, 36 and 52 | |
Secondary | BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) | Disease activity scores and scores evaluating quality of life, range 0-10, and higher values indicate higher disease activity | Change between week 0, 12, 24, 36 and 52 | |
Secondary | BASFI (Bath Ankylosing Spondylitis Functional Index) | Disease activity scores and scores evaluating quality of life, range 0-10, and higher values indicate a higher grade of disability | Change between week 0, 12, 24, 36 and 52 | |
Secondary | CDAI (Clinical Disease Activity Index) | Disease activity scores and scores evaluating quality of life, range 0-76, and scores below 2.8 indicate remission | Change between week 0, 12, 24, 36 and 52 | |
Secondary | Consumption of medicine after 12 months | The proportion who must start or change biological treatment, use of NSAIDs and steroids | Change between baseline and week 52 | |
Secondary | BMI (Body Mass Index) | Nutritional status: Weight (kg) and height (m) will be combined to report BMI (kg/m^2) Change in BMI, waist circumference, fat mass (kg), fat-free mass (kg), fat-free mass index (kg/m2), fat-mass index (kg/m2), handgrip strength | Change between week 0, 12, 24, 36 and 52 | |
Secondary | Waist circumference | Nutritional status: Waist circumference (cm) | Change between week 0, 12, 24, 36 and 52 | |
Secondary | Handgrip strength | Nutritional status: Handgrip strength, measured by a dynamometer (kg) | Change between week 0, 12, 24, 36 and 52 | |
Secondary | Body composition | Estimation of fat mass (kg), fat-free mass (kg), measured by BIA and DXA. Fat-free mass index (kg/m2), and fat-mass index (kg/m2) will be calculated. | Change between week 0, 12, 24, 36 and 52 | |
Secondary | Dietary intake of macro- and micronutrients, based on a dietary registration of 7 days | Energy (E%, kcal) proteins (g and E%) ratio of fatty acids fibers (g) Vitamins and minerals | Week -1,10, 50 | |
Secondary | Dietary intake of macro- and micronutrients, based on a 24h recall. | Energy (E%, kcal) proteins (g and E%) ratio of fatty acids fibers (g) Vitamins and minerals | Week 0, 12, 24, 36, 52 | |
Secondary | Blood lipid profile | HDL (mmol/L) LDL (mmol/L) total cholesterol (mmol/L) triglycerides (mmol/L) | Change from week 0, 12, 24, 36 and 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |